Dexcom

For over 30 years, our team has empowered exceptional entrepreneurs through the provision of capital, expertise, and market access. We exclusively invest in large unmet patient needs in chronic diseases, with an emphasis on cardio & neurovascular disorders, the worldwide leading causes of death and the largest cost driver in the global healthcare systems. Our mission is to improve patient outcomes and quality of life at lower long-term healthcare costs. Investment StrategySector: Medical Technologies Stage: Clinical through Commercial Europe, Israel & North America €5-15 Million per Company Sectors we invest in:Structural Heart Disease Heart Failure Aortic & Peripheral Vascular Disease Neurovascular Disease / Stroke Hypertension Electrophysiology Neuromodulation for Chronic Diseases (e.g. Cardiovascular, Sleep Apnea) Medical Imaging Medical Robotics Patient Monitoring Sectors we do not invest in:Biotech/Pharma Healthcare Services Wellness Products Value Creation Through close collaborations with leading physicians and healthcare providers, we support entrepreneurs from R&D stage through clinical trial execution and commercialization. Besides support with clinical, regulatory and reimbursement strategies, we leverage existing commercial partnerships to provide our portfolio companies with access to a €2bn commercial channel in Europe (Uniphar PLC & CoRRect Medical GmbH).

As part of our investment approach, we developed a structured evaluation process, the “FemHealth Framework.” The first element (re)imagines women’s health as conditions appearing only in women, mostly in women, and differently in women. This concept from the FemHealth Framework (© 2019 FemHealth Ventures) was first published in 2019 and is increasingly thought of as a new lens through which to view women’s health. At FemHealth Ventures, we are excited about the increasing adoption of this broader definition of women’s health and the exciting new treatments it will engender. Only in Women Some conditions appear only in women. Examples include: endometriosis polycystic ovarian syndrome cervical cancer Mostly in Women Some conditions appear mostly in women. Examples include: breast cancer lupus multiple sclerosis Differently in Women Some conditions appear differently in women. Examples include: heart disease diabetes asthma Every cell has a sex A universe of possibilities is opened in women’s health when we start with the most basic building block: our cells. Each of the 30 trillion cells in a woman’s body has a different chromosomal makeup than a man. For example, a skin cell from a woman will have XX chromosomes, but a skin cell from a man will have XY chromosomes. This difference between women and men holds true throughout every single cell in the body. As a result, even the same disease can present differently in women versus men and require distinct treatment paradigms. Women’s health is more than “bikini medicine.” The term “bikini medicine” generally refers to conditions treated by obstetricians or gynecologists. We’ve (re)imagined women’s health as a broad spectrum of conditions that can impact the whole body, ranging from ovarian cancer, to autoimmune disease, to cardiovascular disease, and everything in between. A multitude of possibilities for innovation in women’s health exist. And we are here to help bring them to life.

We build and invest in companies that positively impact human health with smart solutions, breakthrough science and technology. Our focus is on innovation in digital healthcare, connected medical devices, and life sciences We focus on therapeutic and preventive technology solutions addressing unmet needs in some of the most vulnerable segments of society: women, children and the elderly. Digital transformation will continue to shape our lives and has the potential to transform care. We aim to build and support Digital Health & Life Sciences companies working to make healthcare smarter, using data to improve care and outcomes, and reinventing the patient journey. Our vision for the future of healthcare guides our investment strategy. A data driven digital transformation will shape the future of healthcare. The traditional biopharma model will evolve into an integrated model, where prevention, precision cure, and care management will coexist in a highly personalized patient-centric solution. Our goal is to support the creation of life transforming care products and therapies. We believe the future of healthcare lies in supporting the next-generation of founders and teams who will lead us there. What do we look for?Innovation and groundbreaking opportunities in our sectors of focus: digital health, life sciences, tech-enabled care delivery, and connected devices Innovative treatments for Central Nervous System (CNS) disorders, in particular neurodevelopmental disorders, mental health and epilepsy Founders and teams with domain expertise who seek collaborative investment partners Investments that span development and commercial phases, with a focus on early stage opportunities (Pre-Seed to Series A). Our investment approachOur investment approach combines direct investments in early-stage companies with venture creation from bold ideas in global innovation hubs Our goal is to enable talented entrepreneurs to scale more quickly and effectively through access to our capital, enterprise capabilities and consumer touchpoints, while offering expertise and insights from Angelini’s unique perspective. We invest primarily across Europe, North America and Israel, recognizing that healthcare technology innovation is occurring in many cities around the world. We have committed €300M for investments and company creation in digital health and life sciences. What do we commit to you?Active and involved healthcare investors who operate with integrity, approachability, and transparency A team of passionate healthcare and venture capital experts diverse in demographic and experience A track record of success and experience navigating the ups and downs of early-stage company building Access to a world-class advisory board to leverage C-level experience, expertise, and leadership in healthcare

DaVita Venture Group is committed to building partnerships with health care innovators to help improve the lives of patients with kidney disease and related conditions. Together, we believe we can transform the future of patient care for the better. Our Strategy We aim to invest in, acquire, and co-develop products, solutions and businesses that improve care for patients with kidney disease and related conditions. PrioritiesCare Delivery Models: Advancements to expand access to care and improve clinical outcomes through adoption of tech-enabled services, home treatments and value-based care Life Sciences: Pharmaceuticals, medical devices and diagnostics that can improve clinical outcomes and patient experience while reducing costs Digital Health: Products and services that leverage technology, data and connectivity to improve care delivery

We invest to‍ keep people healthy. We invest in companies to drive the shift from traditional sickcare to modern healthcare. People are not destined to become sick as they age. We believe humans can live longer and make the best of all their years. That's why we invest in companies that keep people and our environment healthy. Today, 1 out of 2 people in the world live with a chronic disease. This tragic reality is also the source of more than 80% of all healthcare costs globally. We believe the world can do better. It’s time to break the order of things. We refuse to wait until people get sick to only then be treated. We want to help people maintain and nourish their most precious resources - physical and psychological health. We’re at the front lines of this transformation by investing in pioneering early-stage companies in the US and Europe. We want to build a healthcare system that cares when it matters most. We want people to savor the joyful simplicity of optimal functioning.

Our strategy leverages an extensive hospital system and health plan network of relationships to target attractive market segments, to identify and evaluate investment opportunities, and to support the growth of our portfolio companies. Current Areas of Focus:Administrative Automation Behavioral Health: HCIT & Services Data Security Digital Therapeutics Genomics: Applications & Analytics Patient Safety & Risk Monitoring Pharma Data & Analytics Platforms Social Determinants of Health Virtual Care Models Women’s Health: HCIT & Services